African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

August 1, 2017

Primary Completion Date

October 20, 2024

Study Completion Date

February 28, 2025

Conditions
Ebola
Interventions
BIOLOGICAL

V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine

The rVSVΔG-ZEBOV-GP vaccine is a live attenuated recombinant virus consisting of a single recombinant VSV isolate (11481 nt, strain Indiana) with the gene for the Zaire ebolavirus GP (ZEBOV GP), Kikwit strain replacing the gene for the VSV GP, which has been deleted. This results in a VSV backbone with the ZEBOV GP constituting the envelope of the virus.

OTHER

Saline

Normal saline (0.9%) has been chosen as an inert substance to serve as placebo control.

Trial Locations (1)

H2X 0A9

CHUM, Montreal

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

International Development Research Centre, Canada

OTHER_GOV

collaborator

Dalhousie University

OTHER

collaborator

Université de Montréal

OTHER

collaborator

Coalition for Epidemic Preparedness Innovations

OTHER

lead

Cecile Tremblay

NETWORK